HuGE Literature Finder
Records
1
-
9
Association of SLC22A1,SLCO1B3 Drug Transporter Polymorphisms and Smoking with Disease Risk and Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia. Laboratory medicine 2021 Jun . Mohammadi Fatemeh, Rostami Golale, Assad Dlnya, Shafiei Mohammad, Hamid Mohammad, Jalaeikhoo Has |
Association of the Trough, Peak/Trough Ratio of Imatinib, Pyridine-N-Oxide Imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G With Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients. Frontiers in oncology 2020 9 10 1348. Omran Mervat M, Abdelfattah Raafat, Moussa Heba S, Alieldin Nelly, Shouman Samia |
Effects of Trough Concentration and Solute Carrier Polymorphisms on Imatinib Efficacy in Chinese Patients with Chronic Myeloid Leukemia. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 2020 23 (1): 1-9. Wang Qing, Jiang Zhi-Ping, Zeng Jing, Zhu Yan, Cai Hua-Lin, Xiang Da-Xiong, He Qun, Shi Xiao-Liu, Zhong An-Ni, Zhao Xie-Lan, Xu Pi |
Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients. Hematology (Amsterdam, Netherlands) 2015 Apr 20 (3): 137-42. de Lima Luciene Terezina, Bueno Carolina Tosin, Vivona Douglas, Hirata Rosario Domiguez Crespo, Hirata Mario Hiroyuki, Hungria Vania Tiestsche de Moraes, Chiattone Carlos Sérgio, Zanichelli Maria Aparecida, Chauffaille Maria de Lourdes Lopes Ferrari, Guerra-Shinohara Elvira Mar |
Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenetics and genomics 2013 Feb 23 (2): 53-61. Lopez-Lopez Elixabet, Ballesteros Javier, Piñan Maria A, Sanchez de Toledo José, Garcia de Andoin Nagore, Garcia-Miguel Purificacion, Navajas Aurora, Garcia-Orad Afri |
Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy? Hematology (Amsterdam, Netherlands) 2013 Jan . Bedewy AM, El-Maghraby SM |
Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Therapeutic drug monitoring 2011 Apr 33 (2): 244-50. Yamakawa Yuji, Hamada Akinobu, Nakashima Reiko, Yuki Misato, Hirayama Chie, Kawaguchi Tatsuya, Saito Hideyu |
Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia. Biological & pharmaceutical bulletin 2011 34 (1): 114-9. Nambu Takeru, Hamada Akinobu, Nakashima Reiko, Yuki Misato, Kawaguchi Tatsuya, Mitsuya Hiroaki, Saito Hideyu |
Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. Journal of human genetics 2010 Nov 55 (11): 731-7. Takahashi Naoto, Miura Masatomo, Scott Stuart A, Kagaya Hideaki, Kameoka Yoshihiro, Tagawa Hiroyuki, Saitoh Hirobumi, Fujishima Naohito, Yoshioka Tomoko, Hirokawa Makoto, Sawada Kenic |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 28, 2023
- Content source: